AVAiL Study Shows Longest Survival In Patients With Advanced Non-small Cell Lung Cancer

The final analysis of the Avastin in lung study (AVAiL) in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it also enabled some patients to survive for over 1 year, the longest survival ever reported in patients with this advanced disease. The results were presented today at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. The phase III Roche-sponsored AVAiL study in patients with previously untreated, advanced non-small cell lung cancer (NSCLC), has confirmed that Avastin (bevacizumab) combined with gemcitabine-cisplatin chemotherapy offers a significant improvement in the time that patients live without their d...